Gilead Sciences Appoints New Senior Vice President

Gilead Sciences ( (GILD) ) just unveiled an announcement.

On August 10, 2025, Gilead Sciences announced the appointment of Erin Burkhart as Senior Vice President, Controllership and principal accounting officer, effective September 22, 2025. Ms. Burkhart, with extensive experience in accounting roles at BioMarin Pharmaceutical and Eli Lilly, will succeed Diane E. Wilfong, who will step down on the transition date.

The most recent analyst rating on (GILD) stock is a Hold with a $100.00 price target. To see the full list of analyst forecasts on Gilead Sciences stock, see the GILD Stock Forecast page.

Spark’s Take on GILD Stock

According to Spark, TipRanks’ AI Analyst, GILD is a Neutral.

Gilead Sciences’ overall stock score reflects strong financial performance and positive earnings call highlights, particularly in HIV and oncology segments. However, the lack of technical analysis data and moderate valuation metrics slightly temper the score.

To see Spark’s full report on GILD stock, click here.

More about Gilead Sciences

Gilead Sciences, Inc. is a biotechnology company known for its innovative research and development of antiviral drugs, particularly in the areas of HIV, hepatitis, and influenza. The company focuses on creating life-saving therapies and has a significant presence in the global pharmaceutical market.

Average Trading Volume: 7,393,383

Technical Sentiment Signal: Buy

Current Market Cap: $148.9B

For detailed information about GILD stock, go to TipRanks’ Stock Analysis page.